Information Provided By:
Fly News Breaks for August 19, 2019
VRAY
Aug 19, 2019 | 11:16 EDT
Piper Jaffray analyst Matt O'Brien said he views the results of ViewRay's prostate cancer study as "a highly compelling example of the unique advantages of the MRIdian system" and thinks these results, along with further MRIdian data, should continue to make the selling process for the company easier. The analyst, who expects ViewRay to take market share in upcoming quarters, keeps an Overweight rating on the stock.
News For VRAY From the Last 2 Days
There are no results for your query VRAY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.